Genome-Wide Association Studies and Hepatitis C: Harvesting the Benefits of the Genomic Revolution

Mohammed Eslam; Jacob George

doi:10.1055/s-0035-1567830

Seminars in Liver Disease, Inhaltsverzeichnis

Semin Liver Dis 2015; 35(04): 402-420
DOI: 10.1055/s-0035-1567830

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Genome-Wide Association Studies and Hepatitis C: Harvesting the Benefits of the Genomic Revolution

Authors

Mohammed Eslam

¹Storr Liver Centre, Westmead Millennium Institute, Westmead Hospital and University of Sydney, New South Wales, Australia
Jacob George

¹Storr Liver Centre, Westmead Millennium Institute, Westmead Hospital and University of Sydney, New South Wales, Australia

Abstract

Utilizing genome-wide association studies (GWASs) to examine the variation in hepatitis C virus (HCV) phenotypes has led to quantum improvements in our understanding of both the genetic basis and the underlying pathogenesis of HCV infection. In this context, the discovery of interferon lambda polymorphisms is unique with far reaching implications that extend well beyond HCV to various other liver and extrahepatic diseases. In this review, we summarize the data on the impact of GWASs on our understanding of HCV disease.

Keywords

genome-wide association studies - hepatitis C virus

Volltext

Referenzen

References
1 Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013; 10 (9) 553-562
2 Cowie BC, Allard N, MacLachlan JH. European responses in focus: comparing viral hepatitis and HIV related deaths in Europe 1990–2010 in the Global Burden of Disease Study 2010. In: Proceedings of the 49th annual meeting of the European Association for the Study of the Liver; April 8–13, 2014; London, England
3 The Gastroenterological Society of Australia/Australian Liver Association (GESA/ALA). The economic cost and health burden of liver diseases in Australia. Kingston, Canberra, Australia: Deloitte Access Economics; 2013
4 Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156 (4) 271-278
5 Razavi H, Waked I, Sarrazin C , et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat 2014; 21 (Suppl. 01) 34-59
6 Waked I, Doss W, El-Sayed MH , et al. The current and future disease burden of chronic hepatitis C virus infection in Egypt. Arab J Gastroenterol 2014; 15 (2) 45-52
7 Morin T, Pariente A, Lahmek P, Rabaud C, Silvain C, Cadranel JF ; Association Nationale des Hépato-gastroentérologues des Hôpitaux généraux (ANGH) Société de Pathologie Infectieuse de Langue Française (SPILF) Fédération des Pôles de Référence et Réseaux Hépatites (FPRRH). Acute hepatitis C: analysis of a 126-case prospective, multicenter cohort. Eur J Gastroenterol Hepatol 2010; 22 (2) 157-166
8 Seeff LB. The history of the “natural history” of hepatitis C (1968–2009). Liver Int 2009; 29 (Suppl. 01) 89-99
9 Khattab MA, Eslam M, Alavian SM. Hepatitis C virus as a multifaceted disease: a simple and updated approach for extrahepatic manifestations of hepatitis C virus infection. Hepat Mon 2010; 10 (4) 258-269
10 Eslam M, Khattab MA, Harrison SA. Insulin resistance and hepatitis C: an evolving story. Gut 2011; 60 (8) 1139-1151
11 Yoshida H, Tateishi R, Arakawa Y , et al. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut 2004; 53 (3) 425-430
12 George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology 2009; 49 (3) 729-738
13 Romero-Gómez M, Fernández-Rodríguez CM, Andrade RJ , et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol 2008; 48 (5) 721-727
14 Gragnani L, Fognani E, Piluso A , et al. Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open-label, cohort study. Hepatology 2015; 61 (4) 1145-1153
15 Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000; 31 (3) 777-782
16 Liu CH, Liu CJ, Lin CL , et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008; 47 (10) 1260-1269
17 Romero-Gomez M, Eslam M, Ruiz A, Maraver M. Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment. Liver Int 2011; 31 (4) 443-460
18 Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science 1996; 273 (5281) 1516-1517
19 Haines JL, Hauser MA, Schmidt S , et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005; 308 (5720) 419-421
20 Hindorff LA, MacArthur J, Morales J , et al. A catalog of published genome-wide association studies. Available at: www.genome.gov/gwastudies . Accessed December 8, 2014
21 Romeo S, Kozlitina J, Xing C , et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40 (12) 1461-1465
22 Ge D, Fellay J, Thompson AJ , et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461 (7262) 399-401
23 Suppiah V, Moldovan M, Ahlenstiel G , et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41 (10) 1100-1104
24 Tanaka Y, Nishida N, Sugiyama M , et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41 (10) 1105-1109
25 Rauch A, Kutalik Z, Descombes P , et al; Swiss Hepatitis C Cohort Study; Swiss HIV Cohort Study. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138 (4) 1338-1345 , 1345.e1–1345.e7
26 Moghaddam A, Melum E, Reinton N , et al. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology 2011; 53 (3) 746-754
27 Yu ML, Huang CF, Huang JF , et al. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology 2011; 53 (1) 7-13
28 Mangia A, Thompson AJ, Santoro R , et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010; 139 (3) 821-827 , 827.e1
29 Eslam M, Leung R, Romero-Gomez M , et al. IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. J Hepatol 2014; 61 (2) 235-241
30 Asselah T, De Muynck S, Broët P , et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 2012; 56 (3) 527-532
31 Seto WK, Tsang OT, Liu K , et al. Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection. J Viral Hepat 2013; 20 (7) 470-477
32 Akkarathamrongsin S, Payungporn S, Thong VD , et al. Early viral kinetics during hepatitis C virus genotype 6 treatment according to IL28B polymorphisms. World J Gastroenterol 2014; 20 (30) 10599-10605
33 Antaki N, Bibert S, Kebbewar K , et al. IL28B polymorphisms do not predict response to therapy in chronic hepatitis C with HCV genotype 5. Gut 2012; 61 (11) 1640-1641
34 Thompson AJ, Muir AJ, Sulkowski MS , et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139 (1) 120-129.e18
35 Duggal P, Thio CL, Wojcik GL , et al. Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med 2013; 158 (4) 235-245
36 Thomas DL, Thio CL, Martin MP , et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461 (7265) 798-801
37 Tillmann HL, Thompson AJ, Patel K , et al; German Anti-D Study Group. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 2010; 139 (5) 1586-1592 , 1592.e1
38 Grebely J, Page K, Sacks-Davis R , et al; InC3 Study Group. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology 2014; 59 (1) 109-120
39 Rallón NI, Naggie S, Benito JM , et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS 2010; 24 (8) F23-F29
40 Guo X, Yang G, Yuan J , et al. Genetic variation in interleukin 28B and response to antiviral therapy in patients with dual chronic infection with hepatitis B and C viruses. PLoS ONE 2013; 8 (10) e77911
41 Poordad F, McCone Jr J, Bacon BR , et al; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364 (13) 1195-1206
42 Jacobson IM, McHutchison JG, Dusheiko G , et al; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364 (25) 2405-2416
43 Bacon BR, Gordon SC, Lawitz E , et al; HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364 (13) 1207-1217
44 Zeuzem S, Andreone P, Pol S , et al; REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364 (25) 2417-2428
45 Bota S, Sporea I, Şirli R, Neghină AM, Popescu A, Străin M. Role of interleukin-28B polymorphism as a predictor of sustained virological response in patients with chronic hepatitis C treated with triple therapy: a systematic review and meta-analysis. Clin Drug Investig 2013; 33 (5) 325-331
46 Fried MW, Buti M, Dore GJ , et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013; 58 (6) 1918-1929
47 Jacobson IM, Gordon SC, Kowdley KV , et al; POSITRON Study; FUSION Study. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368 (20) 1867-1877
48 Lawitz E, Mangia A, Wyles D , et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368 (20) 1878-1887
49 Zeuzem S, Soriano V, Asselah T , et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med 2013; 369 (7) 630-639
50 Sulkowski MS, Asselah T, Lalezari J , et al. Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial. Hepatology 2013; 57 (6) 2143-2154
51 Meissner EG, Bon D, Prokunina-Olsson L , et al. IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. J Infect Dis 2014; 209 (11) 1700-1704
52 Chu TW, Kulkarni R, Gane EJ , et al. Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. Gastroenterology 2012; 142 (4) 790-795
53 Poordad F, Lawitz E, Kowdley KV , et al. 1399 12-week interferon-free regimen of ABT-450/r+ABT-333+ribavirin achieved SVR₁₂ in more than 90% of treatment-naive HCV genotype-1-infected subjects and 47% of previous non-responders. J Hepatol 2012; 56 (S2): 549-550
54 Chan K, Lai MN, Groessl EJ , et al. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration. Clin Gastroenterol Hepatol 2013; 11 (11) 1503-1510
55 Sroczynski G, Siebert U. Viral hepatitis: Cost-effectiveness of direct-acting antivirals for chronic hepatitis C. Nat Rev Gastroenterol Hepatol 2013; 10 (10) 572-574
56 Petta S, Cabibbo G, Enea M , et al; WEF Study Group. Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology 2014; 59 (5) 1692-1705
57 Sonneveld MJ, Wong VW, Woltman AM , et al. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology 2012; 142 (3) 513-520.e1
58 Lampertico P, Viganò M, Cheroni C , et al. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology 2013; 57 (3) 890-896
59 Hwa Park N, Jae Kim C. IL28B polymorphisms are not associated with outcomes of hepatitis B virus infection. Hepatology 2011; 54: 1094A
60 Yapali S, Cetintas A, Salman E , et al. IL28B genotype has no impact on spontaneous hepatitis B surface antigen (HBSAG) clearance in inactive carriers: a long term, case matched retrospective cohort study. J Hepatol 2012; 56: S193
61 Bochud PY, Bibert S, Kutalik Z , et al; Swiss Hepatitis C Cohort Study Group; ANRS HC EP 26 Genoscan Study Group. IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology 2012; 55 (2) 384-394
62 Noureddin M, Wright EC, Alter HJ , et al. Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology 2013; 58 (5) 1548-1557
63 Thompson AJ, Clark PJ, Zhu M , et al. Genome wide-association study identifies IL28B polymorphism to be associated with baseline ALT and hepatic necro-inflammatory activity in chronic hepatitis C patients enrolled in the IDEAL study. Hepatology 2010; 52 (4) 1220A-1221A
64 Marabita F, Aghemo A, De Nicola S , et al. Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology 2011; 54 (4) 1127-1134
65 Di Marco V, Bronte F, Calvaruso V , et al. IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. Haematologica 2012; 97 (5) 679-686
66 Fabris C, Falleti E, Cussigh A , et al. IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC. J Hepatol 2011; 54 (4) 716-722
67 Falleti E, Bitetto D, Fabris C , et al. Role of interleukin 28B rs12979860 C/T polymorphism on the histological outcome of chronic hepatitis C: relationship with gender and viral genotype. J Clin Immunol 2011; 31 (5) 891-899
68 Abe H, Ochi H, Maekawa T , et al. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol 2010; 53 (3) 439-443
69 Garrett ME, Abdelmalek MF, Ashley-Koch A , et al. IL28B rs12979860 is not associated with histologic features of NAFLD in a cohort of Caucasian North American patients. J Hepatol 2013; 58 (2) 402-403
70 Petta S, Grimaudo S, Cammà C , et al. IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease. J Hepatol 2012; 56 (6) 1356-1362
71 Eslam M, Hashem AM, Leung R , et al; International Hepatitis C Genetics Consortium (IHCGC). Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nat Commun 2015; 6: 6422
72 Guzmán-Fulgencio M, Berenguer J, García-Álvarez M , et al. IL28B polymorphisms are associated with severity of liver disease in human immunodeficiency virus (HIV) patients coinfected with hepatitis C virus. J Infect 2013; 66 (2) 170-178
73 Bruno S, Thompson AJ, Critelli R , et al. Interferon lambda-3 is not associated with clinical outcome in patients with HCV-induced compensated cirrhosis: a long-term cohort study. Antiviral Res 2015; 113: 27-32
74 Clausen LN, Astvad K, Ladelund S, Larsen MV, Schønning K, Benfield T. Hepatitis C viral load, genotype 3 and interleukin-28B CC genotype predict mortality in HIV and hepatitis C-coinfected individuals. AIDS 2012; 26 (12) 1509-1516
75 Parczewski M, Bander D, Leszczyszyn-Pynka M, Urbańska A, Socha Ł, Boroń-Kaczmarska A. IL28B CC genotype is associated with higher all-cause mortality in antiretroviral-treated HIV-infected patients. AIDS Res Hum Retroviruses 2012; 28 (12) 1640-1646
76 van der Meer AJ, Veldt BJ, Feld JJ , et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308 (24) 2584-2593
77 Probst A, Dang T, Bochud M, Egger M, Negro F, Bochud PY. Role of hepatitis C virus genotype 3 in liver fibrosis progression—a systematic review and meta-analysis. J Viral Hepat 2011; 18 (11) 745-759
78 Lagging M, Askarieh G, Negro F , et al; DITTO-HCV Study Group. Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS ONE 2011; 6 (2) e17232
79 Hodo Y, Honda M, Tanaka A , et al. Association of interleukin-28B genotype and hepatocellular carcinoma recurrence in patients with chronic hepatitis C. Clin Cancer Res 2013; 19 (7) 1827-1837
80 Chang KC, Tseng PL, Wu YY , et al. A polymorphism in interferon L3 is an independent risk factor for development of hepatocellular carcinoma after treatment of hepatitis C virus infection. Clin Gastroenterol Hepatol 2015; 13 (5) 1017-1024
81 Sato M, Kato N, Tateishi R , et al. IL28B minor allele is associated with a younger age of onset of hepatocellular carcinoma in patients with chronic hepatitis C virus infection. J Gastroenterol 2014; 49 (4) 748-754
82 Eurich D, Boas-Knoop S, Bahra M , et al. Role of IL28B polymorphism in the development of hepatitis C virus-induced hepatocellular carcinoma, graft fibrosis, and posttransplant antiviral therapy. Transplantation 2012; 93 (6) 644-649
83 Ren S, Lu J, Du X , et al. Genetic variation in IL28B is associated with the development of hepatitis B-related hepatocellular carcinoma. Cancer Immunol Immunother 2012; 61 (9) 1433-1439
84 Fukuhara T, Taketomi A, Motomura T , et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010; 139 (5) 1577-1585 , 1585.e1–1585.e3
85 Eurich D, Boas-Knoop S, Ruehl M , et al. Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation. Liver Transpl 2011; 17 (3) 289-298
86 Charlton MR, Thompson A, Veldt BJ , et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011; 53 (1) 317-324
87 Duarte-Rojo A, Veldt BJ, Goldstein DD , et al. The course of posttransplant hepatitis C infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables. Transplantation 2012; 94 (2) 197-203
88 Lange CM, Moradpour D, Doehring A , et al. Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. J Hepatol 2011; 55 (2) 322-327
89 Layden JE, Tayo BO, Cotler SJ , et al. Association of genetic variants with rapid fibrosis: progression after liver transplantation for hepatitis C. Transplantation 2014; 97 (10) 1072-1078
90 Veldt BJ, Duarte-Rojo A, Thompson AJ , et al. Recipient IL28B polymorphism is an important independent predictor of posttransplant diabetes mellitus in liver transplant patients with chronic hepatitis C. Am J Transplant 2012; 12 (3) 737-744
91 Duca AM, de la Fuente S, Citores MJ , et al. CC genotype at rs12979860 of IL28B is associated with lower risk of new-onset diabetes after transplantation in adult patients with liver transplantation for hepatitis C cirrhosis. Transplant Proc 2014; 46 (9) 3114-3116
92 Watt KD, Dierkhising R, Fan C , et al. Investigation of PNPLA3 and IL28B genotypes on diabetes and obesity after liver transplantation: insight into mechanisms of disease. Am J Transplant 2013; 13 (9) 2450-2457
93 Piluso A, Giannini C, Fognani E , et al. Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: results of a large, prospective study. J Viral Hepat 2013; 20 (4) e107-e114
94 Sansonno D, Russi S, Serviddio G , et al. Interleukin 28B gene polymorphisms in hepatitis C virus-related cryoglobulinemic vasculitis. J Rheumatol 2014; 41 (1) 91-98
95 Li JH, Lao XQ, Tillmann HL , et al. Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology 2010; 51 (6) 1904-1911
96 Saito H, Ito K, Aoki Y , et al. IL28B polymorphism is associated with the level of LDL cholesterol and the important predictor for the PEG-IFN/RBV treatment with chronic hepatitis. Hepatology 2010; 52 (4) 732A
97 Sheridan DA, Bridge SH, Felmlee DJ , et al. Apolipoprotein-E and hepatitis C lipoviral particles in genotype 1 infection: evidence for an association with interferon sensitivity. J Hepatol 2012; 57 (1) 32-38
98 Chiba-Falek O, Linnertz C, Guyton J , et al. Pleiotropy and allelic heterogeneity in the TOMM40-APOE genomic region related to clinical and metabolic features of hepatitis C infection. Hum Genet 2012; 131 (12) 1911-1920
99 Tillmann HL, Patel K, Muir AJ , et al. Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. J Hepatol 2011; 55 (6) 1195-1200
100 Petta S, Rosso C, Leung R , et al. Effects of IL28B rs12979860 CC genotype on metabolic profile and sustained virologic response in patients with genotype 1 chronic hepatitis C. Clin Gastroenterol Hepatol 2013; 11 (3) 311-317.e1
101 Stättermayer AF, Rutter K, Beinhardt S , et al. Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C. J Hepatol 2012; 57 (3) 492-498
102 Toyoda H, Kumada T. Favorable association between genetic polymorphisms near the IL28B gene and hepatic steatosis: direct or indirect?. J Hepatol 2012; 56 (3) 738-739 , author reply 739
103 Ampuero J, Rojas L, Calle R , et al. 439 I148M PNPLA3 variant promotes steatosis according to viral and IL28B genotype but does not affect sustained viral response in patients with hepatitis C. J Hepatol 2013; 58 (Suppl. 01) S180
104 Veldt BJ, Duarte-Rojo A, Thompson AJ , et al. Donor IL28B TT-polymorphism is associated with increased incidence of hepatic steatosis in liver transplant patients with chronic hepatitis C. J Hepatol 2013; 58 (Suppl. 01) S207-S208
105 Valenti L, Aghemo A, Stättermayer AF. Interaction between IL28B and PNPLA3 genotypes in the pathogenesis of steatosis in chronic hepatitis C non genotype-3 patients. J Hepatol 2012; 56 (5) 1209-1210 , author reply 1210–1212
106 Ampuero J, Del Campo JA, Rojas L , et al. PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C. Ann Hepatol 2014; 13 (4) 356-363
107 Ogawa E, Furusyo N, Murata M , et al. Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1. J Hepatol 2012; 57 (3) 534-540
108 Huang JF, Yu ML, Huang CF , et al. The outcomes of glucose abnormalities in pre-diabetic chronic hepatitis C patients receiving peginterferon plus ribavirin therapy. Liver Int 2012; 32 (6) 962-969
109 Honda M, Sakai A, Yamashita T , et al; Hokuriku Liver Study Group. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010; 139 (2) 499-509
110 Urban TJ, Thompson AJ, Bradrick SS , et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010; 52 (6) 1888-1896
111 Honda M, Shirasaki T, Shimakami T , et al. Hepatic interferon-stimulated genes are differentially regulated in the liver of chronic hepatitis C patients with different interleukin-28B genotypes. Hepatology 2014; 59 (3) 828-838
112 McGilvray I, Feld JJ, Chen L , et al. Hepatic cell-type specific gene expression better predicts HCV treatment outcome than IL28B genotype. Gastroenterology 2012; 142 (5) 1122-1131.e1
113 Raglow Z, Thoma-Perry C, Gilroy R, Wan YJ. IL28B genotype and the expression of ISGs in normal liver. Liver Int 2013; 33 (7) 991-998
114 Zhang S, Kodys K, Li K, Szabo G. Human type 2 myeloid dendritic cells produce interferon-λ and amplify interferon-α in response to hepatitis C virus infection. Gastroenterology 2013; 144 (2) 414-425.e7
115 Yoshio S, Kanto T, Kuroda S , et al. Human blood dendritic cell antigen 3 (BDCA3)(+) dendritic cells are a potent producer of interferon-λ in response to hepatitis C virus. Hepatology 2013; 57 (5) 1705-1715
116 Murata K, Sugiyama M, Kimura T , et al. Ex vivo induction of IFN-λ3 by a TLR7 agonist determines response to Peg-IFN/ribavirin therapy in chronic hepatitis C patients. J Gastroenterol 2014; 49 (1) 126-137
117 Watanabe T, Sugauchi F, Tanaka Y , et al. Hepatitis C virus kinetics by administration of pegylated interferon-α in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene. Gut 2013; 62 (9) 1340-1346
118 Prokunina-Olsson L, Muchmore B, Tang W , et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013; 45 (2) 164-171
119 Bibert S, Roger T, Calandra T , et al; Swiss Hepatitis C Cohort Study. IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J Exp Med 2013; 210 (6) 1109-1116
120 McFarland AP, Horner SM, Jarret A , et al. The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. Nat Immunol 2014; 15 (1) 72-79
121 Smith KR, Suppiah V, O'Connor K , et al; International Hepatitis C Genetics Consortium (IHCGC). Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome Med 2011; 3 (8) 57
122 Thomas E, Gonzalez VD, Li Q , et al. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology 2012; 142 (4) 978-988
123 Park H, Serti E, Eke O , et al. IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection. Hepatology 2012; 56 (6) 2060-2070
124 Sheahan T, Imanaka N, Marukian S , et al. Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness. Cell Host Microbe 2014; 15 (2) 190-202
125 Marcello T, Grakoui A, Barba-Spaeth G , et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006; 131 (6) 1887-1898
126 Bolen CR, Ding S, Robek MD, Kleinstein SH. Dynamic expression profiling of type I and type III interferon-stimulated hepatocytes reveals a stable hierarchy of gene expression. Hepatology 2014; 59 (4) 1262-1272
127 Jilg N, Lin W, Hong J , et al. Kinetic differences in the induction of interferon stimulated genes by interferon-α and interleukin 28B are altered by infection with hepatitis C virus. Hepatology 2014; 59 (4) 1250-1261
128 Giugliano S, Kriss M, Golden-Mason L , et al. Hepatitis C virus infection induces autocrine interferon signaling by human liver endothelial cells and release of exosomes, which inhibits viral replication. Gastroenterology 2015; 148 (2) 392-402.e13
129 Winau F, Hegasy G, Weiskirchen R , et al. Ito cells are liver-resident antigen-presenting cells for activating T cell responses. Immunity 2007; 26 (1) 117-129
130 Wang Y, Li J, Wang X, Ye L, Zhou Y, Ho W. Induction of interferon-λ contributes to Toll-like receptor-3-activated hepatic stellate cell-mediated hepatitis C virus inhibition in hepatocytes. J Viral Hepat 2013; 20 (6) 385-394
131 Griffiths SJ, Koegl M, Boutell C , et al. A systematic analysis of host factors reveals a Med23-interferon-λ regulatory axis against herpes simplex virus type 1 replication. PLoS Pathog 2013; 9 (8) e1003514
132 Akay E, Patel M, Conibear T, Chaggar T, Haque T. Interleukin 28B gene polymorphisms and Epstein-Barr virus-associated lymphoproliferative diseases. Intervirology 2014; 57 (2) 112-115
133 Egli A, Levin A, Santer DM , et al. Immunomodulatory function of interleukin 28B during primary infection with cytomegalovirus. J Infect Dis 2014; 210 (5) 717-727
134 Bravo D, Solano C, Giménez E , et al. Effect of the IL28B Rs12979860 C/T polymorphism on the incidence and features of active cytomegalovirus infection in allogeneic stem cell transplant patients. J Med Virol 2014; 86 (5) 838-844
135 Bibert S, Wojtowicz A, Taffé P , et al; Swiss HIV Cohort Study. The IFNL3/4 ΔG variant increases susceptibility to cytomegalovirus retinitis among HIV-infected patients. AIDS 2014; 28 (13) 1885-1889
136 Manuel O, Wójtowicz A, Bibert S , et al. Influence of IFNL3/4 polymorphisms on the incidence of cytomegalovirus infection after solid-organ transplantation. J Infect Dis 2015; 211 (6) 906-914
137 Treviño A, Lopez M, Vispo E , et al; HTLV Spanish Study Group. Development of tropical spastic paraparesis in human T-lymphotropic virus type 1 carriers is influenced by interleukin 28B gene polymorphisms. Clin Infect Dis 2012; 55 (1) e1-e4
138 Sanabani SS, Nukui Y, Pereira J , et al. Lack of evidence to support the association of a single IL28B genotype SNP rs12979860 with the HTLV-1 clinical outcomes and proviral load. BMC Infect Dis 2012; 12: 374
139 Sommereyns C, Paul S, Staeheli P, Michiels T. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 2008; 4 (3) e1000017
140 Baldridge MT, Nice TJ, McCune BT , et al. Commensal microbes and interferon-λ determine persistence of enteric murine norovirus infection. Science 2015; 347 (6219) 266-269
141 Nice TJ, Baldridge MT, McCune BT , et al. Interferon λ cures persistent murine norovirus infection in the absence of adaptive immunity. Science 2015; 347 (6219) 269-273
142 Pott J, Mahlakõiv T, Mordstein M , et al. IFN-lambda determines the intestinal epithelial antiviral host defense. Proc Natl Acad Sci U S A 2011; 108 (19) 7944-7949
143 Mordstein M, Kochs G, Dumoutier L , et al. Interferon-lambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLoS Pathog 2008; 4 (9) e1000151
144 Mordstein M, Neugebauer E, Ditt V , et al. Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J Virol 2010; 84 (11) 5670-5677
145 Contoli M, Message SD, Laza-Stanca V , et al. Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med 2006; 12 (9) 1023-1026
146 Thomas DL, Astemborski J, Rai RM , et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284 (4) 450-456
147 Grebely J, Raffa JD, Lai C, Krajden M, Conway B, Tyndall MW. Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users. Can J Gastroenterol 2007; 21 (7) 447-451
148 Muir AJ, Bornstein JD, Killenberg PG ; Atlantic Coast Hepatitis Treatment Group. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004; 350 (22) 2265-2271
149 Conjeevaram HS, Fried MW, Jeffers LJ , et al; Virahep-C Study Group. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131 (2) 470-477
150 Key FM, Peter B, Dennis MY , et al. Selection on a variant associated with improved viral clearance drives local, adaptive pseudogenization of interferon lambda 4 (IFNL4). PLoS Genet 2014; 10 (10) e1004681
151 Suppiah V, Gaudieri S, Armstrong NJ , et al; International Hepatitis C Genetics Consortium (IHCGC). IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European cohort: a cross-sectional study. PLoS Med 2011; 8 (9) e1001092
152 Raj T, Kuchroo M, Replogle JM, Raychaudhuri S, Stranger BE, De Jager PL. Common risk alleles for inflammatory diseases are targets of recent positive selection. Am J Hum Genet 2013; 92 (4) 517-529
153 Forni D, Cagliani R, Pozzoli U , et al. A 175 million year history of T cell regulatory molecules reveals widespread selection, with adaptive evolution of disease alleles. Immunity 2013; 38 (6) 1129-1141
154 Casto AM, Feldman MW. Genome-wide association study SNPs in the human genome diversity project populations: does selection affect unlinked SNPs with shared trait associations?. PLoS Genet 2011; 7 (1) e1001266
155 Barreiro LB, Quintana-Murci L. From evolutionary genetics to human immunology: how selection shapes host defence genes. Nat Rev Genet 2010; 11 (1) 17-30
156 Single RM, Martin MP, Gao X , et al. Global diversity and evidence for coevolution of KIR and HLA. Nat Genet 2007; 39 (9) 1114-1119
157 Akuta N, Suzuki F, Kawamura Y , et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 2007; 46 (3) 403-410
158 Kobayashi M, Suzuki F, Akuta N , et al. Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus. J Gastroenterol 2012; 47 (5) 596-605
159 Akuta N, Suzuki F, Seko Y , et al. Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis. Hepatology 2012; 56 (6) 2134-2141
160 Hayes CN, Kobayashi M, Akuta N , et al. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut 2011; 60 (2) 261-267
161 Lawitz E, Poordad FF, Pang PS , et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014; 383 (9916) 515-523
162 Miura M, Maekawa S, Sato M , et al. Deep sequencing analysis of variants resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection. Hepatol Res 2014; 44 (14) E360-E367
163 Rose R, Markov PV, Lam TT, Pybus OG. Viral evolution explains the associations among hepatitis C virus genotype, clinical outcomes, and human genetic variation. Infect Genet Evol 2013; 20: 418-421
164 Patin E, Kutalik Z, Guergnon J , et al; Swiss Hepatitis C Cohort Study Group; International Hepatitis C Genetics Consortium; French ANRS HC EP 26 Genoscan Study Group. Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. Gastroenterology 2012; 143 (5) 1244-1252.e1 , 12
165 Urabe Y, Ochi H, Kato N , et al. A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC region. J Hepatol 2013; 58 (5) 875-882
166 Calvaruso V, Bronte F, Grimaudo S, Di Cristina A, Di Marco V. Rs4374383 single nucleotide polymorphism of mertk gene influences the progression of liver fibrosis in thalassemia major patients with chronic hepatitis C virus infection. J Hepatol 2013; 58: S182
167 Rüeger S, Bochud PY, Dufour JF , et al. Impact of common risk factors of fibrosis progression in chronic hepatitis C. Gut 2015; 64 (10) 1605-1615
168 Rojas L, Ampuero J, Del Campo JA , et al. Validation study of the impact of SNPs from GWAS associated with fibrosis progression in chronic hepatitis C (HCV). Hepatology 2013; 58 (4) (Suppl. 01) 327A
169 Tamaki N, Kurosaki M, Yasui Y , et al. Association of genetic polymorphisms with fibrosis progression in chronic hepatitis c after failure of interferon therapy. J Hepatol 2014; 60 (1) (Suppl. 01) S315
170 Kumar V, Kato N, Urabe Y , et al. Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet 2011; 43 (5) 455-458
171 Miki D, Ochi H, Hayes CN , et al. Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers. Nat Genet 2011; 43 (8) 797-800
172 Harada Y, Kanehira M, Fujisawa Y , et al. Cell-permeable peptide DEPDC1-ZNF224 interferes with transcriptional repression and oncogenicity in bladder cancer cells. Cancer Res 2010; 70 (14) 5829-5839
173 Seng TJ, Ichimura K, Liu L, Tingby O, Pearson DM, Collins VP. Complex chromosome 22 rearrangements in astrocytic tumors identified using microsatellite and chromosome 22 tile path array analysis. Genes Chromosomes Cancer 2005; 43 (2) 181-193
174 Ishida S, Picard F, Rudolf G , et al. Mutations of DEPDC5 cause autosomal dominant focal epilepsies. Nat Genet 2013; 45 (5) 552-555
175 Ma N, Zhang X, Yu F , et al. Role of IFN-ks, IFN-ks related genes and the DEPDC5 gene in hepatitis B virus-related liver disease. J Viral Hepat 2014; 21 (7) e29-e38
176 Nagaoki Y, Aikata H, Kobayashi T , et al. Hepatocellular carcinoma development of hepatitis C virus patients with eradication to interferon therapy: a large scale, long-term study of 2266 patients. Hepatology 2014; 60 (Suppl. 01) 1162A-1163A
177 Fellay J, Thompson AJ, Ge D , et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010; 464 (7287) 405-408
178 Tanaka Y, Kurosaki M, Nishida N , et al. Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C. Hum Mol Genet 2011; 20 (17) 3507-3516
179 Thompson AJ, Clark PJ, Singh A , et al. Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. J Hepatol 2012; 56 (2) 313-319
180 Zignego AL, Wojcik GL, Cacoub P , et al. Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis. Genes Immun 2014; 15 (7) 500-505
181 McClellan J, King MC. Genetic heterogeneity in human disease. Cell 2010; 141 (2) 210-217
182 Manolio TA, Collins FS, Cox NJ , et al. Finding the missing heritability of complex diseases. Nature 2009; 461 (7265) 747-753
183 Ward LD, Kellis M. Interpreting noncoding genetic variation in complex traits and human disease. Nat Biotechnol 2012; 30 (11) 1095-1106